Canada · Delayed Price · Currency is CAD Biosenta Statistics
Total Valuation
Biosenta has a market cap or net worth of CAD 1.65 million. The enterprise value is 8.84 million.
| Market Cap | 1.65M |
| Enterprise Value | 8.84M |
Important Dates
The next estimated earnings date is Thursday, August 27, 2026.
| Earnings Date | Aug 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biosenta has 36.65 million shares outstanding. The number of shares has increased by 3.61% in one year.
| Current Share Class | 36.65M |
| Shares Outstanding | 36.65M |
| Shares Change (YoY) | +3.61% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 14.18% |
| Owned by Institutions (%) | n/a |
| Float | 31.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 423.20 |
| PB Ratio | -0.15 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.00
| Current Ratio | 0.00 |
| Quick Ratio | 0.00 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -16.82 |
| Interest Coverage | -1.29 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -721.99% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 11.39% |
| Weighted Average Cost of Capital (WACC) | 9.53% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.04 |
| Inventory Turnover | 0.07 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -66.67% in the last 52 weeks. The beta is 0.05, so Biosenta's price volatility has been lower than the market average.
| Beta (5Y) | 0.05 |
| 52-Week Price Change | -66.67% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.12 |
| Relative Strength Index (RSI) | 32.93 |
| Average Volume (20 Days) | 17,916 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Biosenta had revenue of CAD 3,897 and -2.39 million in losses. Loss per share was -0.07.
| Revenue | 3,897 |
| Gross Profit | 1,275 |
| Operating Income | -1.26M |
| Pretax Income | -2.39M |
| Net Income | -2.39M |
| EBITDA | -1.26M |
| EBIT | -1.26M |
| Loss Per Share | -0.07 |
Balance Sheet
The company has 10,376 in cash and 7.21 million in debt, with a net cash position of -7.20 million or -0.20 per share.
| Cash & Cash Equivalents | 10,376 |
| Total Debt | 7.21M |
| Net Cash | -7.20M |
| Net Cash Per Share | -0.20 |
| Equity (Book Value) | -11.07M |
| Book Value Per Share | -0.31 |
| Working Capital | -11.11M |
Cash Flow
In the last 12 months, operating cash flow was -426,806 and capital expenditures -1,647, giving a free cash flow of -428,453.
| Operating Cash Flow | -426,806 |
| Capital Expenditures | -1,647 |
| Depreciation & Amortization | 2,251 |
| Net Borrowing | 434,615 |
| Free Cash Flow | -428,453 |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | 32.72% |
| Operating Margin | -32,357.30% |
| Pretax Margin | -61,335.18% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Biosenta does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.61% |
| Shareholder Yield | -3.61% |
| Earnings Yield | -144.93% |
| FCF Yield | -25.98% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 28, 2016. It was a reverse split with a ratio of 0.0666666666.
| Last Split Date | Jun 28, 2016 |
| Split Type | Reverse |
| Split Ratio | 0.0666666666 |
Scores
Biosenta has an Altman Z-Score of -591.52 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -591.52 |
| Piotroski F-Score | 2 |